Wednesday, 27 August 2025
A new study, led by experts at the 糖心原创, has found that people who test positive following a stool test for symptoms of bowel cancer, had double the risk of death after one year than people who had negative tests, and most of the deaths were due to other causes.
The data from the study, which is led by Professor David Humes in the School of Medicine and supported by the National Institute for Health and Care Research (NIHR), will now be used to look at whether this certain test could be used to test for other types of diseases, as well as bowel cancer.
Bowel cancer is the third most common cancer and second highest cause of cancer death in the UK. This new study, published in the journal , looked at FITs (faecal immunochemical tests). FITs are used by GPs to detect microscopic traces of blood in people’s poo who have symptoms of bowel cancer (colorectal cancer).
If the test is ‘negative’, then the risk of bowel cancer is very low and no further tests are needed.
“There has been a huge increase in the number of FITs being done each year but there are many other reasons why someone might have a 'positive' result,” says Dr Francesca Malcolm, a Clinical Research Fellow in Colorectal Surgery and NIHR Doctoral Fellow in the School of Medicine at the University and lead author of the study.
Research from bowel cancer screening has linked a 'positive' FIT with an increased risk of dying from diseases other than bowel cancer. No studies have looked at whether this is the case in patients having FIT for symptoms of bowel cancer.
“We have done the first study looking into the risk of death in patients who have had a ‘positive’ FIT with symptoms of bowel cancer,” adds Dr Malcolm.
The team used anonymous data which was collected from nearly 50,000 patients living in Nottingham between 2017 and 2022 who had a FIT due to symptoms of bowel cancer.
In the year following a FIT due to bowel cancer symptoms, 1,971 (4%) patients died.
In our study, after one-year patients with a 鈥榩ositive鈥� FIT had double the risk of death compared to patients with a 鈥榥egative鈥� test. Whilst this is a test for bowel cancer most of deaths were due to other causes. We hope to use these results to improve how FIT is used in future. The next step is to look at causes of death after a 鈥榩ositive鈥� FIT as this will help decide whether other diseases should be tested for after a 'positive' result.鈥�
The full study can be found .
Story credits
More information is available Dr Francesca Malcolm in the School of Medicine at francescaligori.malcolm@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.